• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Completes Sale of Needle Rock Farms Assets

    5/8/25 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email

    Further Strengthens Balance Sheet Cash Position

    MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses.

    "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in cash increases our cash position which will fund our revenue growth strategies for 2025 that are already generating positive results year-to-date even before we see the benefit of our new VLN® and Partner VLN® launches."

    22nd Century will report its complete first quarter results on May 13, 2025, with a conference call the same day.

    About 22nd Century Group, Inc.

    22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.

    We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.

    Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN® products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion.

    Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets.

    VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.

    Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

    Learn more about VLN® at tryvln.com.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 20, 2025. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Investor Relations & Media Contact

    Matt Kreps

    Investor Relations

    22nd Century Group

    [email protected]

    214-597-8200



    Primary Logo

    Get the next $XXII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Financials

    Live finance-specific insights

    See more
    • 22nd Century Group Completes Sale of Needle Rock Farms Assets

      Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

      5/8/25 5:07:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction

      Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb

      5/7/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Reports Fourth Quarter and Full Year 2024 Financial Results

      Launches 2025 Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple Categories  Announces First VLN® Partner Brands with Smoker Friendly Ready for Shipment in Q2 2025, Additional Partner VLN® Brands in Discussion MOCKSVILLE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the fourth quarter and year-ended December 31, 2024, and provided an update on recent business highlights. Fourth Quarter and Full Year 2024 Financial Results (compared to Thi

      3/20/25 6:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

      For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

      12/23/21 9:06:12 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:37:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salhany Lucille S was granted 2,472 shares, increasing direct ownership by 49,440% to 2,477 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:35:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Arno Andrew was granted 4,237 shares, increasing direct ownership by 9,015% to 4,284 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:30:19 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    SEC Filings

    See more
    • SEC Form S-3 filed by 22nd Century Group Inc.

      S-3 - 22nd Century Group, Inc. (0001347858) (Filer)

      5/8/25 5:00:51 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form 10-K/A filed by 22nd Century Group Inc.

      10-K/A - 22nd Century Group, Inc. (0001347858) (Filer)

      4/30/25 9:10:37 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - 22nd Century Group, Inc. (0001347858) (Filer)

      4/30/25 9:09:14 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 22nd Century Group Completes Sale of Needle Rock Farms Assets

      Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

      5/8/25 5:07:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction

      Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb

      5/7/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group to Announce First Quarter 2025 Results on May 13, 2025

      MOCKSVILLE, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, will host a webcast on Tuesday, May 13, 2025, at 8:00 AM ET to discuss its 2025 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day. During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results, discuss progress made in the recent months and update plans for the 2025 year. The live and archived webcast will be accessible on the Events web page i

      5/5/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      12/3/24 11:18:54 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      11/14/24 5:56:57 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by 22nd Century Group Inc.

      SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

      10/23/24 7:27:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      9/12/24 5:00:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      5/31/24 4:05:20 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      1/8/24 8:04:11 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    See more
    • 22nd Century Announces Resignation of John Miller as President of Tobacco

      Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

      5/30/24 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

      BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

      9/12/22 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

      CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea

      6/16/22 8:30:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

      Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      7/21/22 9:12:19 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on 22nd Century Group with a new price target

      Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      6/15/22 7:42:24 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Roth Capital initiated coverage on 22nd Century Group with a new price target

      Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

      3/8/22 9:21:23 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care